Your browser doesn't support javascript.
loading
Infliximab in patients with psoriasis and other inflammatory diseases: evaluation of adverse events in the treatment of 168 patients
Antonio, João Roberto; Sanmiguel, Jessica; Cagnon, Giovana Viotto; Augusto, Marília Silveira Faeda; Godoy, Moacir Fernandes de; Pozetti, Eurides Maria Oliveira.
  • Antonio, João Roberto; Faculdade Estadual de Medicina de São José do Rio Preto. São José do Rio Preto. BR
  • Sanmiguel, Jessica; Faculdade Estadual de Medicina de São José do Rio Preto. São José do Rio Preto. BR
  • Cagnon, Giovana Viotto; Faculdade Estadual de Medicina de São José do Rio Preto. São José do Rio Preto. BR
  • Augusto, Marília Silveira Faeda; Faculdade Estadual de Medicina de São José do Rio Preto. São José do Rio Preto. BR
  • Godoy, Moacir Fernandes de; Faculdade Estadual de Medicina de São José do Rio Preto. São José do Rio Preto. BR
  • Pozetti, Eurides Maria Oliveira; Faculdade Estadual de Medicina de São José do Rio Preto. São José do Rio Preto. BR
An. bras. dermatol ; 91(3): 306-310, tab, graf
Article in English | LILACS | ID: lil-787309
ABSTRACT
Abstract

Background:

Psoriasis is immune-mediated chronic inflammatory disease with preference for skin and joints. The skin involvement occurs by hyperproliferation and abnormal differentiation of keratinocytes. It is associated with comorbidities, mainly related to the clinical manifestations of the metabolic syndrome. Increased TNF-alpha expression (TNF-α) is related to its pathophysiology. Infliximab is an intravenous drug that acts neutralizing the biological activity of TNF-α and prevents the binding of the molecule to the target cell receptor, inhibiting cell proliferation of psoriasis and other diseases mediated by TNF-α. A lot of infusion reactions have been described in the literature.

Objective:

To evaluate the adverse effects of intravenous treatment with infliximab, analyzing patients with psoriasis compared to those with other chronic inflammatory diseases (rheumatoid arthritis, ankylosing spondylitis, Crohn's disease and ulcerative colitis).

Method:

Analysis of medical records and adverse events of 168 patients undergoing infliximab infusion for psoriasis and chronic inflammatory diseases treatment.

Results:

168 patients who have used infliximab were evaluated, 24 had psoriasis and 144 had chronic inflammatory diseases. Only 2 (8.3%) patients with psoriasis showed adverse events requiring treatment discontinuation, and just 6 (4.2%) female patients with chronic inflammatory diseases experienced adverse events.

Conclusion:

Infliximab is a safe drug, with a low percentage of adverse events and there were more adverse events in women with chronic inflammatory diseases and in patients who received more infliximab infusions.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Psoriasis / Antirheumatic Agents / Infliximab Type of study: Observational study / Prevalence study / Risk factors Limits: Adult / Female / Humans / Male Language: English Journal: An. bras. dermatol Journal subject: Dermatology Year: 2016 Type: Article Affiliation country: Brazil Institution/Affiliation country: Faculdade Estadual de Medicina de São José do Rio Preto/BR

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Psoriasis / Antirheumatic Agents / Infliximab Type of study: Observational study / Prevalence study / Risk factors Limits: Adult / Female / Humans / Male Language: English Journal: An. bras. dermatol Journal subject: Dermatology Year: 2016 Type: Article Affiliation country: Brazil Institution/Affiliation country: Faculdade Estadual de Medicina de São José do Rio Preto/BR